RxDoctor Payments Data

Doris Reid, APRN

Family · Simpsonville, SCNPI 1376099887

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 53.2% of the total. Among family clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,371in general payments, 2019–2025

Across 426 payments — averaging $59.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$14K
  • Neurocrine Biosciences, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AbbVie$1K
  • plus $5K from 21 others

What the payments were for

  • Consulting fees$1,4976%
  • Speaking & faculty fees$10,42041%
  • Travel & lodging$8813%
  • Food & beverage$12,26448%
  • Education$3091%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,371 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$7,901
Medicare patients
34
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine35$195,276
Austedo XrDeutetrabenazine25$181,318
VraylarCariprazine Hcl59$87,528
RexultiBrexpiprazole39$76,600
AristadaAripiprazole Lauroxil15$57,802
TrintellixVortioxetine Hydrobromide33$39,794
CaplytaLumateperone Tosylate21$39,076
Invega SustennaPaliperidone Palmitate12$37,518
Lurasidone Hcl65$20,620
BelsomraSuvorexant33$14,613
QuviviqDaridorexant Hcl15$8,048
VyvanseLisdexamfetamine Dimesylate16$6,319
Aripiprazole53$3,062
Clozapine20$2,097
Lamotrigine ErLamotrigine12$2,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$13,501$376,59460 claims
AbbVieVraylar$1,176$87,52859 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,229$76,60039 claims
Alkermes, Inc.Aristada$745$57,80215 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$132$46,11349 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,466$39,07621 claims
Johnson & JohnsonInvega Sustenna$600$37,51812 claims
Idorsia Pharmaceuticals US IncQuviviq$46$8,04815 claims
Almatica Pharma LLCSertraline Hcl$198$28663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →